Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	3,463	1,810
General and administrative	3,742	2,179
Restructuring and other costs	0	1,022
Total operating expenses	7,205	5,011
Loss from operations	(7,205)	(5,011)
Other income, net	92	232
Net loss	$ (7,113)	$ (4,779)
Net loss per share - basic	$ (0.86)	$ (1.05)
Net loss per share - diluted	$ (0.86)	$ (1.05)
Weighted average common shares outstanding - basic	8,301,798	4,541,167
Weighted average common shares outstanding - diluted	8,301,798	4,541,167
Comprehensive loss:
Net loss	$ (7,113)	$ (4,779)
Other comprehensive gain:
Unrealized gain on investments, net of tax of $0	0	38
Total other comprehensive gain	0	38
Total comprehensive loss	$ (7,113)	$ (4,741)